Multifaceted link between cancer and inflammation

Bioscience Reports

Volumn 32, Issue 1, 2012, Pages 1-15

  Sethi, Gautam ^a   Shanmugam, Muthu K ^a   Ramachandran, Lalitha ^a   Kumar, Alan Prem ^a,b   Tergaonkar, Vinay ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Activator protein 1 (AP 1); Hypoxia inducible factor 1 (HIF 1 ); Matrix metalloproteinase (MMP); Nuclear factor B (NF B); Oncogene; Signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

5 LOX PROTEIN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; ONCOPROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BRAF GENE; BRAIN CANCER; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CHRONIC INFLAMMATION; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GENE FUNCTION; HEAD AND NECK CANCER; HUMAN; INFLAMMATORY DISEASE; LUNG CARCINOMA; MELANOMA; METASTASIS; NONHUMAN; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE RAS; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RET GENE; REVIEW; SIGNAL TRANSDUCTION; TRK GENE; TUMOR VASCULARIZATION; UROGENITAL TRACT CANCER;

ARACHIDONATE 5-LIPOXYGENASE; CHEMOKINES; CHRONIC DISEASE; CYCLOOXYGENASE 2; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; INFLAMMATION MEDIATORS; LIFE STYLE; MATRIX METALLOPROTEINASES; NEOPLASMS; NF-KAPPA B; ONCOGENES; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

NICOTIANA TABACUM;

EID: 84863012160     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20100136     Document Type: Review

References (221)

1. Mantovani, A. (2009) Cancer: inflaming metastasis. Nature 457, 36-37
2. Grivennikov, S. I., Greten, F. R. and Karin, M. (2010) Immunity, inflammation, and cancer. Cell 140, 883-899
3. Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Cancer-related inflammation. Nature 454, 436-444
4. Aggarwal, B. B., Vijayalekshmi, R. V. and Sung, B. (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 15, 425-430
5. Demaria, S., Pikarsky, E., Karin, M., Coussens, L. M., Chen, Y. C., El-Omar, E. M., Trinchieri, G., Dubinett, S. M., Mao, J. T., Szabo, E. et al. (2010) Cancer and inflammation: promise for biologic therapy. J. Immunother. 33, 335-351
6. Colotta, F., Allavena, P., Sica, A., Garlanda, C. and Mantovani, A. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073-1081
7. Balkwill, F. and Mantovani, A. (2001) Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (Pubitemid 32173595)
8. Aggarwal, B. B. and Gehlot, P. (2009) Inflammation and cancer: how friendly is the relationship for cancer patients? Curr. Opin. Pharmacol. 9, 351-369
9. Karin, M., Lawrence, T. and Nizet, V. (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124, 823-835 (Pubitemid 43261455)
10. Anand, P., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Tharakan, S. T., Lai, O. S., Sung, B. and Aggarwal, B. B. (2008) Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 25, 2097-2116
11. Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K. and Sethi, G. (2006) Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72, 1605-1621 (Pubitemid 44666739)
12. Balkwill, F. and Mantovani, A. (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 87, 401-406
13. Aggarwal, B. (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745-756
14. Sethi, G., Sung, B. and Aggarwal, B. B. (2008) TNF: a master switch for inflammation to cancer. Front. Biosci. 13, 5094-5107 (Pubitemid 351599660)
15. Balkwill, F. (2009) Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361-371
16. Balkwill, F. (2006) TNF-α in promotion and progression of cancer. Cancer Metastasis Rev. 25, 409-416
17. Digel, W., Schoniger, W., Stefanic, M., Janssen, H., Buck, C., Schmid, M., Raghavachar, A. and Porzsolt, F. (1990) Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood 76, 1607-1613 (Pubitemid 20364026)
18. Liu, R. Y., Fan, C., Mitchell, S., Chen, Q., Wu, J. and Zuckerman, K. S. (1998) The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-α to transduce a proliferative signal in the human megakaryoblastic leukemic cell line Mo7e. Cancer Res. 58, 2217-2223 (Pubitemid 28232911)
19. Tsukasaki, K., Miller, C. W., Kubota, T., Takeuchi, S., Fujimoto, T., Ikeda, S., Tomonaga, M. and Koeffler, H. P. (2001) Tumor necrosis factor α polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res. 61, 3770-3774 (Pubitemid 32694991)
20. Montesano, R., Soulie, P., Eble, J. A. and Carrozzino, F. (2005) Tumour necrosis factor α confers an invasive, transformed phenotype on mammary epithelial cells. J. Cell Sci. 118, 3487-3500 (Pubitemid 41246102)
21. Kalthoff, H., Roeder, C., Gieseking, J., Humburg, I. and Schmiegel, W. (1993) Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor α. Proc. Natl. Acad. Sci. U.S.A. 90, 8972-8976 (Pubitemid 23306433)
22. Schmiegel, W., Roeder, C., Schmielau, J., Rodeck, U. and Kalthoff, H. (1993) Tumor necrosis factor α induces the expression of transforming growth factor α and the epidermal growth factor receptor in human pancreatic cancer cells. Proc. Natl. Acad. Sci. U.S.A. 90, 863-867 (Pubitemid 23053910)
23. Naylor, M. S., Stamp, G. W., Foulkes, W. D., Eccles, D. and Balkwill, F. R. (1993) Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J. Clin. Invest. 91, 2194-2206 (Pubitemid 23141496)
24. Duarte, I., Santos, A., Sousa, H., Catarino, R., Pinto, D., Matos, A., Pereira, D., Moutinho, J., Canedo, P., Machado, J. C. and Medeiros, R. (2005) G-308A TNF-α polymorphism is associated with an increased risk of invasive cervical cancer. Biochem. Biophys. Res. Commun. 334, 588-592 (Pubitemid 40982407)
25. Aggarwal, B. B., Schwarz, L., Hogan, M. E. and Rando, R. F. (1996) Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. Cancer Res. 56, 5156-5164 (Pubitemid 26383030)
26. Nabors, L. B., Suswam, E., Huang, Y., Yang, X., Johnson, M. J. and King, P. H. (2003) Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res. 63, 4181-4187 (Pubitemid 36917944)
27. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E. and Ben-Neriah, Y. (2004) NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466 (Pubitemid 39329586)
28. Orosz, P., Echtenacher, B., Falk, W., Ruschoff, J., Weber, D. and Mannel, D. N. (1993) Enhancement of experimental metastasis by tumor necrosis factor. J. Exp. Med. 177, 1391-1398 (Pubitemid 23117129)
29. Ferrajoli, A., Keating, M. J., Manshouri, T., Giles, F. J., Dey, A., Estrov, Z., Koller, C. A., Kurzrock, R., Thomas, D. A., Faderl, S. et al. (2002) The clinical significance of tumor necrosis factor-αplasma level in patients having chronic lymphocytic leukemia. Blood 100, 1215-1219 (Pubitemid 34864274)
30. Wolf, J. S., Chen, Z., Dong, G., Sunwoo, J. B., Bancroft, C. C., Capo, D. E., Yeh, N. T., Mukaida, N. and Van Waes, C. (2001) IL (interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin. Cancer Res. 7, 1812-1820 (Pubitemid 32708653)
31. Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K. et al. (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84, 114-122
32. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J. and Neckers, L. (2003) IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17, 2115-2117
33. Abramov, Y., Anteby, S. O., Fasouliotis, S. J. and Barak, V. (2002) The role of inflammatory cytokines in Meigs' syndrome. Obstet. Gynecol. 99, 917-919 (Pubitemid 34442419)
34. Hong, D. S., Angelo, L. S. and Kurzrock, R. (2007) Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110, 1911-1928 (Pubitemid 350036849)
35. Naugler, W. E. and Karin, M. (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14, 109-119
36. Lin, W. W. and Karin, M. (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117, 1175-1183
37. Angelo, L. S., Talpaz, M. and Kurzrock, R. (2002) Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res. 62, 932-940 (Pubitemid 34126975)
38. Kai, H., Kitadai, Y., Kodama, M., Cho, S., Kuroda, T., Ito, M., Tanaka, S., Ohmoto, Y. and Chayama, K. (2005) Involvement of proinflammatory cytokines IL-1β and IL-6 in progression of human gastric carcinoma. Anticancer Res. 25, 709-713 (Pubitemid 40546835)
39. Klein, B. and Bataille, R. (1992) Cytokine network in human multiple myeloma. Hematol. Oncol. Clin. North Am. 6, 273-284
40. Chung, Y. C. and Chang, Y. F. (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol. 83, 222-226
41. Sharma, R., Zucknick, M., London, R., Kacevska, M., Liddle, C. and Clarke, S. J. (2008) Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin. Colorectal Cancer 7, 331-337
42. Waugh, D. J. and Wilson, C. (2008) The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735-6741
43. Xu, L. and Fidler, I. J. (2000) Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res. 60, 4610-4616 (Pubitemid 32103647)
44. Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X. D., Gudas, J. M. and Bar-Eli, M. (2002) Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161, 125-134 (Pubitemid 34760778)
45. Bendre, M. S., Margulies, A. G., Walser, B., Akel, N. S., Bhattacharrya, S., Skinner, R. A., Swain, F., Ramani, V., Mohammad, K. S., Wessner, L. L. et al. (2005) Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res. 65, 11001-11009 (Pubitemid 41713370)
46. Maxwell, P. J., Gallagher, R., Seaton, A., Wilson, C., Scullin, P., Pettigrew, J., Stratford, I. J., Williams, K. J., Johnston, P. G. and Waugh, D. J. (2007) HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26, 7333-7345 (Pubitemid 350115971)
47. Asarch, A., Barak, O., Loo, D. S. and Gottlieb, A. B. (2008) Th17 cells: a new therapeutic target in inflammatory dermatoses. J. Dermatolog. Treat. 19, 318-326
48. Tartour, E., Fossiez, F., Joyeux, I., Galinha, A., Gey, A., Claret, E., Sastre-Garau, X., Couturier, J., Mosseri, V., Vives, V. et al. (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 59, 3698-3704 (Pubitemid 29381875)
49. Numasaki, M., Fukushi, J., Ono, M., Narula, S. K., Zavodny, P. J., Kudo, T., Robbins, P. D., Tahara, H. and Lotze, M. T. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620-2627 (Pubitemid 36857622)
50. Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A., McAllister, F., Hishinuma, T., Goto, J., Lotze, M. T., Kolls, J. K. and Sasaki, H. (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 175, 6177-6189 (Pubitemid 41508106)
51. Wang, D., Dubois, R. N. and Richmond, A. (2009) The role of chemokines in intestinal inflammation and cancer. Curr. Opin. Pharmacol. 9, 688-696
52. Lu, H., Ouyang, W. and Huang, C. (2006) Inflammation, a key event in cancer development. Mol. Cancer Res. 4, 221-233
53. Kollmar, O., Rupertus, K., Scheuer, C., Junker, B., Tilton, B., Schilling, M. K. and Menger, M. D. (2007) Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 9, 862-870 (Pubitemid 47623426)
54. Owen, J. D., Strieter, R., Burdick, M., Haghnegahdar, H., Nanney, L., Shattuck-Brandt, R. and Richmond, A. (1997) Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine β and γ proteins. Int. J. Cancer 73, 94-103 (Pubitemid 27445996)
55. Yuecheng, Y. and Xiaoyan, X. (2007) Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. Eur. J. Cancer Prev. 16, 430-435 (Pubitemid 47550003)
56. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N. et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (Pubitemid 32225831)
57. Johrer, K., Zelle-Rieser, C., Perathoner, A., Moser, P., Hager, M., Ramoner, R., Gander, H., Holtl, L., Bartsch, G., Greil, R. and Thurnher, M. (2005) Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma. Clin. Cancer Res. 11, 2459-2465 (Pubitemid 40569440)
58. Schwarze, S. R., Luo, J., Isaacs, W. B. and Jarrard, D. F. (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64, 67-74 (Pubitemid 40734740)
59. Kim, S. Y., Lee, C. H., Midura, B. V., Yeung, C., Mendoza, A., Hong, S. H., Ren, L., Wong, D., Korz, W., Merzouk, A. et al. (2008) Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin. Exp. Metastasis 25, 201-211
60. Weinberg, R. A. (1994) Oncogenes and tumor suppressor genes. CA Cancer J. Clin. 44, 160-170
61. Croce, C. M. (2008) Oncogenes and cancer. N. Engl. J. Med. 358, 502-511
62. Borrello, M. G., Degl'Innocenti, D. and Pierotti, M. A. (2008) Inflammation and cancer: the oncogene-driven connection. Cancer Lett. 267, 262-270
63. Grivennikov, S. I. and Karin, M. (2010) Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 20, 65-71
64. Liu, J., Yang, G., Thompson-Lanza, J. A., Glassman, A., Hayes, K., Patterson, A., Marquez, R. T., Auersperg, N., Yu, Y., Hahn, W. C. et al. (2004) A genetically defined model for human ovarian cancer. Cancer Res. 64, 1655-1663 (Pubitemid 38428686)
65. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D. and Fidler, I. J. (1998) Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. 90, 447-454 (Pubitemid 28160636)
66. Ancrile, B., Lim, K. H. and Counter, C. M. (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21, 1714-1719 (Pubitemid 47076470)
67. Meyer, N. and Penn, L. Z. (2008) Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990
68. Shchors, K., Shchors, E., Rostker, F., Lawlor, E. R., Brown-Swigart, L. and Evan, G. I. (2006) The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β. Genes Dev. 20, 2527-2538 (Pubitemid 44396838)
69. Soucek, L., Lawlor, E. R., Soto, D., Shchors, K., Swigart, L. B. and Evan, G. I. (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13, 1211-1218 (Pubitemid 47530639)
70. Arighi, E., Borrello, M. G. and Sariola, H. (2005) RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 16, 441-467 (Pubitemid 41022013)
71. Hwang, E. S. and Bowen, P. E. (2007) DNA damage, a biomarker of carcinogenesis: its measurement and modulation by diet and environment. Crit. Rev. Food Sci. Nutr. 47, 27-50
72. Schetter, A. J., Heegaard, N. H. and Harris, C. C. (2010) Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31, 37-49
73. Klaunig, J. E., Kamendulis, L. M. and Hocevar, B. A. (2010) Oxidative stress and oxidative damage in carcinogenesis. Toxicol. Pathol. 38, 96-109
74. Babior, B. M. (2000) Phagocytes and oxidative stress. Am. J. Med. 109, 33-44
75. Closa, D. and Folch-Puy, E. (2004) Oxygen free radicals and the systemic inflammatory response. IUBMB Life 56, 185-191 (Pubitemid 38828746)
76. Kwak, M. K. and Kensler, T. W. (2010) Targeting NRF2 signaling for cancer chemoprevention. Toxicol. Appl. Pharmacol. 244, 66-76
77. Marnett, L. J. (2000) Oxyradicals and DNA damage. Carcinogenesis 21, 361-370
78. Shen, H. M. and Ong, C. N. (1996) Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat. Res. 366, 23-44
79. Nishigori, C., Hattori, Y. and Toyokuni, S. (2004) Role of reactive oxygen species in skin carcinogenesis. Antioxid. Redox Signal. 6, 561-570 (Pubitemid 38625376)
80. Aggarwal, B. B. and Shishodia, S. (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71, 1397-1421
81. Aggarwal, B. B., Van Kuiken, M. E., Iyer, L. H., Harikumar, K. B. and Sung, B. (2009) Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp. Biol. Med. (Maywood) 234, 825-849
82. Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Tharakan, S. T., Sung, B. and Anand, P. (2008) Potential of spice-derived phytochemicals for cancer prevention. Planta Med. 74, 1560-1569
83. Surh, Y. J. and Kundu, J. K. (2007) Cancer preventive phytochemicals as speed breakers in inflammatory signaling involved in aberrant COX-2 expression. Curr. Cancer Drug Targets 7, 447-458
84. Einspahr, J. G., Krouse, R. S., Yochim, J. M., Danenberg, P. V., Danenberg, K. D., Bhattacharyya, A. K., Martinez, M. E. and Alberts, D. S. (2003) Association between cyclooxygenase expression and colorectal adenoma characteristics. Cancer Res. 63, 3891-3893 (Pubitemid 36917900)
85. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F. and Taketo, M. M. (1996) Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803-809 (Pubitemid 26404280)
86. Oshima, M., Murai, N., Kargman, S., Arguello, M., Luk, P., Kwong, E., Taketo, M. M. and Evans, J. F. (2001) Chemoprevention of intestinal polyposis in the ApcΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61, 1733-1740 (Pubitemid 34292612)
87. Liu, W., Reinmuth, N., Stoeltzing, O., Parikh, A. A., Tellez, C., Williams, S., Jung, Y. D., Fan, F., Takeda, A., Akagi, M. et al. (2003) Cyclooxygenase-2 is up-regulated by interleukin-1 β in human colorectal cancer cells via multiple signaling pathways. Cancer Res. 63, 3632-3636 (Pubitemid 36793046)
88. Pold, M., Zhu, L. X., Sharma, S., Burdick, M. D., Lin, Y., Lee, P. P., Pold, A., Luo, J., Krysan, K., Dohadwala, M. et al. (2004) Cyclooxygenase-2- dependent expression of angiogenic CXC chemokines ENA-78/CXC ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res. 64, 1853-1860 (Pubitemid 38428711)
89. Hashimoto, N., Inayama, M., Fujishima, M. and Shiozaki, H. (2007) Clinicopathologic significance of expression of cyclooxygenase-2 in human esophageal squamous cell carcinoma. Hepatogastroenterology 54, 758-760 (Pubitemid 46903717)
90. Shono, T., Tofilon, P. J., Bruner, J. M., Owolabi, O. and Lang, F. F. (2001) Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61, 4375-4381 (Pubitemid 32685762)
91. Kim, Y. B., Kim, G. E., Cho, N. H., Pyo, H. R., Shim, S. J., Chang, S. K., Park, H. C., Suh, C. O., Park, T. K. and Kim, B. S. (2002) Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 95, 531-539
92. Cetin, M., Buyukberber, S., Demir, M., Sari, I., Deniz, K., Eser, B., Altuntas, F., Camci, C., Ozturk, A., Turgut, B. et al. (2005) Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. Am. J. Hematol. 80, 169-173 (Pubitemid 41579537)
93. Pidgeon, G. P., Lysaght, J., Krishnamoorthy, S., Reynolds, J. V., O'Byrne, K., Nie, D. and Honn, K. V. (2007) Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 26, 503-524 (Pubitemid 350115127)
94. Cuendet, M. and Pezzuto, J. M. (2000) The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol. Drug Interact. 17, 109-157 (Pubitemid 32049022)
95. Shureiqi, I. and Lippman, S. M. (2001) Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 61, 6307-6312 (Pubitemid 32783228)
96. Boado, R. J., Pardridge, W. M., Vinters, H. V. and Black, K. L. (1992) Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. Proc. Natl. Acad. Sci. U.S.A. 89, 9044-9048
97. Ye, Y. N., Liu, E. S., Shin, V. Y., Wu, W. K. and Cho, C. H. (2004) Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology 203, 179-188 (Pubitemid 39200948)
98. Hennig, R., Grippo, P., Ding, X. Z., Rao, S. M., Buchler, M. W., Friess, H., Talamonti, M. S., Bell, R. H. and Adrian, T. E. (2005) 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 65, 6011-6016 (Pubitemid 40994383)
99. Jiang, W. G., Douglas-Jones, A. G. and Mansel, R. E. (2006) Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot. Essent. Fatty Acids 74, 125-134 (Pubitemid 43082137)
100. Faronato, M., Muzzonigro, G., Milanese, G., Menna, C., Bonfigli, A. R., Catalano, A. and Procopio, A. (2007) Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histol. Histopathol. 22, 1109-1118 (Pubitemid 47470305)
101. Cruz-Munoz, W. and Khokha, R. (2008) The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit. Rev. Clin. Lab. Sci. 45, 291-338 (Pubitemid 351883130)
102. Thiery, J. P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454
103. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z. and Hanahan, D. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744
104. Coussens, L. M., Tinkle, C. L., Hanahan, D. and Werb, Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490
105. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T. et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (Pubitemid 34130608)
106. Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L. and Massague, J. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (Pubitemid 41112921)
107. Chen, X. L., Wang, L. C., Zhang, W. G., Chen, X. Y. and Sun, Z. M. (2008) Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao 28, 1254-1258
108. Hu, Z. L., Wen, J. F., Shen, M. and Liu, Y. (2006) Expressions of TGIF, MMP9 and VEGF proteins and their clinicopathological relationship in gastric cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31, 70-74 (Pubitemid 43385814)
109. Gu, Z. D., Li, J. Y., Li, M., Gu, J., Shi, X. T., Ke, Y. and Chen, K. N. (2005) Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am. J. Gastroenterol. 100, 1835-1843 (Pubitemid 41648441)
110. Sakata, K., Satoh, M., Someya, M., Asanuma, H., Nagakura, H., Oouchi, A., Nakata, K., Kogawa, K., Koito, K., Hareyama, M. and Himi, T. (2004) Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 100, 356-365 (Pubitemid 38063646)
111. Karin, M. (2006) Nuclear factor-κB in cancer development and progression. Nature 441, 431-436
112. Sethi, G. and Tergaonkar, V. (2009) Potential pharmacological control of the NF-κB pathway. Trends Pharmacol. Sci. 30, 313-321
113. Sethi, G., Sung, B. and Aggarwal, B. B. (2008) Nuclear factor-κB activation: from bench to bedside. Exp. Biol. Med. (Maywood) 233, 21-31
114. Tergaonkar, V., Correa, R. G., Ikawa, M. and Verma, I. M. (2005) Distinct roles of IκB proteins in regulating constitutive NF-κB activity. Nat. Cell Biol. 7, 921-923 (Pubitemid 41486295)
115. Karin, M. (2006) NF-κB and cancer: mechanisms and targets. Mol. Carcinog. 45, 355-361
116. Vallabhapurapu, S. and Karin, M. (2009) Regulation and function of NF-κB transcription factors in the immune system. Annu. Rev. Immunol. 27, 693-733
117. Shen, H. M. and Tergaonkar, V. (2009) NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14, 348-363
118. Ahn, K. S., Sethi, G. and Aggarwal, B. B. (2007) Nuclear factor-κB: from clone to clinic. Curr. Mol. Med. 7, 619-637
119. Ahn, K. S. and Aggarwal, B. B. (2005) Transcription factor NF-κB: a sensor for smoke and stress signals. Ann. N.Y. Acad. Sci. 1056, 218-233 (Pubitemid 43030980)
120. Biswas, S. K., Bist, P., Dhillon, M. K., Kajiji, T., Del Fresno, C., Yamamoto, M., Lopez-Collazo, E., Akira, S. and Tergaonkar, V. (2007) Role for MyD88-independent, TRIF pathway in lipid A/TLR4-induced endotoxin tolerance. J. Immunol. 179, 4083-4092
121. Lee, K. G., Xu, S., Wong, E. T., Tergaonkar, V. and Lam, K. P. (2008) Bruton's tyrosine kinase separately regulates NFκB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells. J. Biol. Chem. 283, 11189-11198
122. Wong, E. T. and Tergaonkar, V. (2009) Roles of NF-κB in health and disease: mechanisms and therapeutic potential. Clin. Sci. 116, 451-465
123. Mantovani, A. (2010) Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 10, 369-373
124. Li, F. and Sethi, G. (2010) Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 1805, 167-180
125. Baud, V. and Karin, M. (2009) Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33-40
126. Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., Kagnoff, M. F. and Karin, M. (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (Pubitemid 39061110)
127. Naugler, W. E. and Karin, M. (2008) NF-κB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19-26
128. Karin, M. (2008) The IκB kinase - a bridge between inflammation and cancer. Cell Res. 18, 334-342
129. Chew, J., Biswas, S., Shreeram, S., Humaidi, M., Wong, E. T., Dhillion, M. K., Teo, H., Hazra, A., Fang, C. C., Lopez-Collazo, E. et al. (2009) WIP1 phosphatase is a negative regulator of NF-κB signalling. Nat. Cell Biol. 11, 659-666
130. Tergaonkar, V., Pando, M., Vafa, O., Wahl, G. and Verma, I. (2002) p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 1, 493-503 (Pubitemid 41039129)
131. Tergaonkar, V. and Perkins, N. D. (2007) p53 and NF-κB crosstalk: IKKα tips the balance. Mol. Cell 26, 158-159 (Pubitemid 46617342)
132. Xia, Y., Padre, R. C., De Mendoza, T. H., Bottero, V., Tergaonkar, V. B. and Verma, I. M. (2009) Phosphorylation of p53 by IκB kinase 2 promotes its degradation by β-TrCP. Proc. Natl. Acad. Sci. U.S.A. 106, 2629-2634
133. Irelan, J. T., Murphy, T. J., DeJesus, P. D., Teo, H., Xu, D., Gomez-Ferreria, M. A., Zhou, Y., Miraglia, L. J., Rines, D. R., Verma, I. M. et al. (2007) A role for IκB kinase 2 in bipolar spindle assembly. Proc. Natl. Acad. Sci. U.S.A. 104, 16940-16945 (Pubitemid 350210969)
134. Dey, A., Wong, E. T., Bist, P., Tergaonkar, V. and Lane, D. P. (2007) Nutlin-3 inhibits the NFκB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle 6, 2178-2185 (Pubitemid 47450420)
135. Dey, A., Wong, E. T., Cheok, C. F., Tergaonkar, V. and Lane, D. P. (2008) R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 15, 263-273
136. Dey, A., Tergaonkar, V. and Lane, D. P. (2008) Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways. Nat. Rev. Drug Discov. 7, 1031-1040
137. Mantovani, A. and Sica, A. (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237
138. Uzzo, R. G., Clark, P. E., Rayman, P., Bloom, T., Rybicki, L., Novick, A. C., Bukowski, R. M. and Finke, J. H. (1999) Alterations in NFκB activation in T lymphocytes of patients with renal cell carcinoma. J. Natl. Cancer Inst. 91, 718-721 (Pubitemid 29234567)
139. Balkwill, F., Charles, K. A. and Mantovani, A. (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217 (Pubitemid 40568680)
140. Biswas, S. K., Gangi, L., Paul, S., Schioppa, T., Saccani, A., Sironi, M., Bottazzi, B., Doni, A., Vincenzo, B., Pasqualini, F. et al. (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). Blood 107, 2112-2122 (Pubitemid 43289397)
141. Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P. and Mantovani, A. (2008) Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349-355
142. Saccani, A., Schioppa, T., Porta, C., Biswas, S. K., Nebuloni, M., Vago, L., Bottazzi, B., Colombo, M. P., Mantovani, A. and Sica, A. (2006) p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 66, 11432-11440 (Pubitemid 46009975)
143. Nickoloff, B. J., Ben-Neriah, Y. and Pikarsky, E. (2005) Inflammation and cancer: is the link as simple as we think? J. Invest. Dermatol. 124, x-xiv (Pubitemid 40847392)
144. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S. and Ruco, L. (1992) The origin and function of tumor-associated macrophages. Immunol. Today 13, 265-270
145. Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C. and Balkwill, F. R. (2008) "Re- educating" tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 205, 1261-1268
146. Ihle, J. N. (1996) STATs: signal transducers and activators of transcription. Cell 84, 331-334
147. Yu, H. and Jove, R. (2004) The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4, 97-105 (Pubitemid 38198738)
148. Bowman, T., Garcia, R., Turkson, J. and Jove, R. (2000) STATs in oncogenesis. Oncogene 19, 2474-2488 (Pubitemid 30339203)
149. Yu, H., Pardoll, D. and Jove, R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809
150. Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S. and Sung, B. (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann. N.Y. Acad. Sci. 1171, 59-76
151. Turkson, J. and Jove, R. (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19, 6613-6626 (Pubitemid 32197700)
152. Aggarwal, B. B., Sethi, G., Ahn, K. S., Sandur, S. K., Pandey, M. K., Kunnumakkara, A. B., Sung, B. and Ichikawa, H. (2006) Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N.Y. Acad. Sci. 1091, 151-169 (Pubitemid 47092233)
153. Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P. and Zucman-Rossi, J. (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204
154. Li, Y., Du, H., Qin, Y., Roberts, J., Cummings, O. W. and Yan, C. (2007)
155. Ernst, M., Najdovska, M., Grail, D., Lundgren-May, T., Buchert, M., Tye, H., Matthews, V. B., Armes, J., Bhathal, P. S., Hughes, N. R. et al. (2008) STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 118, 1727-1738 (Pubitemid 351632376)
156. Bronte-Tinkew, D. M., Terebiznik, M., Franco, A., Ang, M., Ahn, D., Mimuro, H., Sasakawa, C., Ropeleski, M. J., Peek, Jr, R. M. and Jones, N. L. (2009) Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. Cancer Res. 69, 632-639
157. Sano, S., Chan, K. S., Kira, M., Kataoka, K., Takagi, S., Tarutani, M., Itami, S., Kiguchi, K., Yokoi, M., Sugasawa, K. et al. (2005) Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Cancer Res. 65, 5720-5729 (Pubitemid 40911175)
158. Arredondo, J., Chernyavsky, A. I., Jolkovsky, D. L., Pinkerton, K. E. and Grando, S. A. (2006) Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of α7 nicotinic receptor in oral keratinocytes. FASEB J. 20, 2093-2101 (Pubitemid 44953908)
159. Grivennikov, S. I. and Karin, M. (2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11-19
160. Dauer, D. J., Ferraro, B., Song, L., Yu, B., Mora, L., Buettner, R., Enkemann, S., Jove, R. and Haura, E. B. (2005) Stat3 regulates genes common to both wound healing and cancer. Oncogene 24, 3397-3408 (Pubitemid 40756241)
161. Park, E. J., Lee, J. H., Yu, G. Y., He, G., Ali, S. R., Holzer, R. G., Osterreicher, C. H., Takahashi, H. and Karin, M. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208
162. Angel, P. and Karin, M. (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072, 129-157 (Pubitemid 121007534)
163. Eferl, R. and Wagner, E. F. (2003) AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3, 859-868 (Pubitemid 37383716)
164. Shaulian, E. (2010) AP-1 - the Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal. 22, 894-899
165. Young, M. R., Yang, H. S. and Colburn, N. H. (2003) Promising molecular targets for cancer prevention: AP-1, NF-κB and Pdcd4. Trends Mol. Med. 9, 36-41 (Pubitemid 36139254)
166. Chang, L. and Karin, M. (2001) Mammalian MAP kinase signalling cascades. Nature 410, 37-40 (Pubitemid 32225829)
167. Matthews, C. P., Colburn, N. H. and Young, M. R. (2007) AP-1 a target for cancer prevention. Curr. Cancer Drug Targets 7, 317-324 (Pubitemid 46849236)
168. Ozanne, B. W., Spence, H. J., McGarry, L. C. and Hennigan, R. F. (2007) Transcription factors control invasion: AP-1 the first among equals. Oncogene 26, 1-10 (Pubitemid 46067326)
169. Bos, T. J., Monteclaro, F. S., Mitsunobu, F., Ball, Jr, A. R., Chang, C. H., Nishimura, T. and Vogt, P. K. (1990) Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev. 4, 1677-1687
170. Verde, P., Casalino, L., Talotta, F., Yaniv, M. and Weitzman, J. B. (2007) Deciphering AP-1 function in tumorigenesis: fraternizing on target promoters. Cell Cycle 6, 2633-2639 (Pubitemid 350224046)
171. Dong, Z., Crawford, H. C., Lavrovsky, V., Taub, D., Watts, R., Matrisian, L. M. and Colburn, N. H. (1997) A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol. Carcinog. 19, 204-212 (Pubitemid 27360138)
172. Bos, T. J., Margiotta, P., Bush, L. and Wasilenko, W. (1999) Enhanced cell motility and invasion of chicken embryo fibroblasts in response to Jun over-expression. Int. J. Cancer 81, 404-410 (Pubitemid 29165199)
173. Briggs, J., Chamboredon, S., Castellazzi, M., Kerry, J. A. and Bos, T. J. (2002) Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21, 7077-7091 (Pubitemid 35252982)
174. Cohen, S. B., Waha, A., Gelman, I. H. and Vogt, P. K. (2001) Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts. Oncogene 20, 141-146 (Pubitemid 32150259)
175. Black, E. J., Clair, T., Delrow, J., Neiman, P. and Gillespie, D. A. (2004) Microarray analysis identifies autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene 23, 2357-2366 (Pubitemid 38496791)
176. Eferl, R., Ricci, R., Kenner, L., Zenz, R., David, J. P., Rath, M. and Wagner, E. F. (2003) Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112, 181-192 (Pubitemid 36144108)
177. Young, M. R., Li, J. J., Rincon, M., Flavell, R. A., Sathyanarayana, B. K., Hunziker, R. and Colburn, N. (1999) Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc. Natl. Acad. Sci. U.S.A. 96, 9827-9832 (Pubitemid 29398817)
178. Wang, Z. Q., Grigoriadis, A. E., Mohle-Steinlein, U. and Wagner, E. F. (1991) A novel target cell for c-fos-induced oncogenesis: development of chondrogenic tumours in embryonic stem cell chimeras. EMBO J. 10, 2437-2450 (Pubitemid 21905717)
179. Li, J. J., Rhim, J. S., Schlegel, R., Vousden, K. H. and Colburn, N. H. (1998) Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 16, 2711-2721 (Pubitemid 28279336)
180. Guillemin, K. and Krasnow, M. A. (1997) The hypoxic response: huffing and HIFing. Cell 89, 9-12 (Pubitemid 27180579)
181. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732
182. Ryan, H. E., Lo, J. and Johnson, R. S. (1998) HIF-1 α is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015 (Pubitemid 28254373)
183. Dehne, N. and Brune, B. (2009) HIF-1 in the inflammatory microenvironment. Exp. Cell Res. 315, 1791-1797
184. Hellwig-Burgel, T., Rutkowski, K., Metzen, E., Fandrey, J. and Jelkmann, W. (1999) Interleukin-1β and tumor necrosis factor-αstimulate DNA binding of hypoxia-inducible factor-1. Blood 94, 1561-1567 (Pubitemid 29411306)
185. Poon, E., Harris, A. L. and Ashcroft, M. (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev. Mol. Med. 11, e26
186. Koh, M. Y., Spivak-Kroizman, T. R. and Powis, G. (2010) HIF-1αand cancer therapy. Recent Results Cancer Res. 180, 15-34
187. Dajee, M., Lazarov, M., Zhang, J. Y., Cai, T., Green, C. L., Russell, A. J., Marinkovich, M. P., Tao, S., Lin, Q., Kubo, Y. and Khavari, P. A. (2003) NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421, 639-643 (Pubitemid 36227672)
188. He, G., Yu, G. Y., Temkin, V., Ogata, H., Kuntzen, C., Sakurai, T., Sieghart, W., Peck-Radosavljevic, M., Leffert, H. L. and Karin, M. (2010) Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 17, 286-297
189. Geborek, P., Nitelius, E., Noltorp, S., Petri, H., Jacobsson, L., Larsson, L., Saxne, T. and Leden, I. (2005) Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales. Ann. Rheum. Dis. 64, 1805-1807 (Pubitemid 41667171)
190. Wu, Z. H., Wong, E. T., Shi, Y., Niu, J., Chen, Z., Miyamoto, S. and Tergaonkar, V. (2010) ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol. Cell 40, 75-86
191. Teo, H., Ghosh, S., Luesch, H., Ghosh, A., Wong, E. T., Malik, N., Orth, A., de Jesus, P., Perry, A. S., Oliver, J. D. et al. (2010) Telomere-independent Rap1 is an IKK adaptor and regulates NF-κB-dependent gene expression. Nat. Cell Biol. 12, 758-767
192. Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y., Spalding, C., Elloumi, H. Z., Paulson, M. L. et al. (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452, 773-776 (Pubitemid 351521078)
193. Cai, T., Mazzoli, S., Meacci, F., Tinacci, G., Nesi, G., Zini, E. and Bartoletti, R. (2007) Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma. J. Urol. 178, 1906-1911
194. Ishikawa, H., Tsuyama, N., Obata, M. and Kawano, M. M. (2006) Mitogenic signals initiated via interleukin-6 receptor complexes in cooperation with other transmembrane molecules in myelomas. J. Clin. Exp. Hematop. 46, 55-66
195. Knupfer, H. and Preiss, R. (2010) Serum interleukin-6 levels in colorectal cancer patients: a summary of published results. Int. J. Colorectal Dis. 25, 135-140
196. Vidal-Vanaclocha, F., Mendoza, L., Telleria, N., Salado, C., Valcarcel, M., Gallot, N., Carrascal, T., Egilegor, E., Beaskoetxea, J. and Dinarello, C. A. (2006) Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev. 25, 417-434 (Pubitemid 44922359)
197. Melisi, D., Niu, J., Chang, Z., Xia, Q., Peng, B., Ishiyama, S., Evans, D. B. and Chiao, P. J. (2009) Secreted interleukin-1αinduces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-κB. Mol. Cancer Res. 7, 624-633
198. McCarron, S. L., Edwards, S., Evans, P. R., Gibbs, R., Dearnaley, D. P., Dowe, A., Southgate, C., Easton, D. F., Eeles, R. A. and Howell, W. M. (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 62, 3369-3372 (Pubitemid 34651380)
199. Singh, R. K. and Varney, M. L. (2000) IL-8 expression in malignant melanoma: implications in growth and metastasis. Histol. Histopathol. 15, 843-849 (Pubitemid 30488567)
200. Brat, D. J., Bellail, A. C. and Van Meir, E. G. (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 7, 122-133 (Pubitemid 40590513)
201. Arlt, A., Vorndamm, J., Muerkoster, S., Yu, H., Schmidt, W. E., Folsch, U. R. and Schafer, H. (2002) Autocrine production of interleukin 1β confers constitutive nuclear factor κB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 62, 910-916 (Pubitemid 34126972)
202. Xu, S. and Lam, K. P. (2001) B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell Biol. 21, 4067-4074 (Pubitemid 32476467)
203. Sparmann, A. and Bar-Sagi, D. (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458 (Pubitemid 39469981)
204. Saijo, Y., Tanaka, M., Miki, M., Usui, K., Suzuki, T., Maemondo, M., Hong, X., Tazawa, R., Kikuchi, T., Matsushima, K. and Nukiwa, T. (2002) Proinflammatory cytokine IL-1 β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J. Immunol. 169, 469-475 (Pubitemid 34686169)
205. Kimsey, T. F., Campbell, A. S., Albo, D., Wilson, M. and Wang, T. N. (2004) Co-localization of macrophage inflammatory protein-3α(Mip-3α) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J. 10, 374-380 (Pubitemid 44313545)
206. Porcile, C., Bajetto, A., Barbero, S., Pirani, P. and Schettini, G. (2004) CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann. N.Y. Acad. Sci. 1030, 162-169 (Pubitemid 40378910)
207. Kundu, N. and Fulton, A. M. (2002) Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 62, 2343-2346 (Pubitemid 34411715)
208. Chang, S. H., Ai, Y., Breyer, R. M., Lane, T. F. and Hla, T. (2005) The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res. 65, 4496-4499 (Pubitemid 40740782)
209. Subbarayan, V., Sabichi, A. L., Llansa, N., Lippman, S. M. and Menter, D. G. (2001) Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-α in normal and malignant prostate cells. Cancer Res. 61, 2720-2726 (Pubitemid 32685860)
210. Denkert, C., Kobel, M., Berger, S., Siegert, A., Leclere, A., Trefzer, U. and Hauptmann, S. (2001) Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 61, 303-308 (Pubitemid 32095731)
211. Goulet, A. C., Einsphar, J. G., Alberts, D. S., Beas, A., Burk, C., Bhattacharyya, A., Bangert, J., Harmon, J. M., Fujiwara, H., Koki, A. and Nelson, M. A. (2003) Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol. Ther. 2, 713-718
212. Souza, R. F., Shewmake, K., Beer, D. G., Cryer, B. and Spechler, S. J. (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 60, 5767-5772
213. Wild, P. J., Kunz-Schughart, L. A., Stoehr, R., Burger, M., Blaszyk, H., Simon, R., Gasser, T., Mihatsch, M., Sauter, G. and Hartmann, A. (2005) High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int. J. Oncol. 27, 385-391
214. Farrow, B. and Evers, B. M. (2002) Inflammation and the development of pancreatic cancer. Surg. Oncol. 10, 153-169 (Pubitemid 34520439)
215. Mendes, R. A., Carvalho, J. F. and Waal, I. (2009) An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol. 45, e124-e128
216. Su, J. L., Shih, J. Y., Yen, M. L., Jeng, Y. M., Chang, C. C., Hsieh, C. Y., Wei, L. H., Yang, P. C. and Kuo, M. L. (2004) Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 64, 554-564
217. Heuze-Vourc'h, N., Zhu, L., Krysan, K., Batra, R. K., Sharma, S. and Dubinett, S. M. (2003) Abnormal interleukin 10Rα expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res. 63, 766-770 (Pubitemid 36231973)
218. Forones, N. M., Kawamura, K. Y., Segreto, H. R., Artigiani Neto, R., Focchi, G. R. and Oshima, C. T. (2008) Expression of COX-2 in stomach carcinogenesis. J. Gastrointest. Cancer 39, 4-10
219. Tang, X., Sun, Y. J., Half, E., Kuo, M. T. and Sinicrope, F. (2002) Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 62, 4903-4908 (Pubitemid 34984412)
220. Zhang, L., Zhang, W. P., Hu, H., Wang, M. L., Sheng, W. W., Yao, H. T., Ding, W., Chen, Z. and Wei, E. Q. (2006) Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology 26, 99-106
221. Ye, Y. N., Wu, W. K., Shin, V. Y., Bruce, I. C., Wong, B. C. and Cho, C. H. (2005) Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26, 827-834 (Pubitemid 41214346)